IRIS Accounts Production v24.2.0.383 06937090 Board of Directors Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh069370902022-12-31069370902023-12-31069370902023-01-012023-12-31069370902021-12-31069370902022-01-012022-12-31069370902022-12-3106937090ns15:EnglandWales2023-01-012023-12-3106937090ns14:PoundSterling2023-01-012023-12-3106937090ns10:Director12023-01-012023-12-3106937090ns10:Director22023-01-012023-12-3106937090ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3106937090ns10:SmallEntities2023-01-012023-12-3106937090ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3106937090ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3106937090ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3106937090ns10:FullAccounts2023-01-012023-12-3106937090ns10:RegisteredOffice2023-01-012023-12-3106937090ns5:CurrentFinancialInstruments2023-12-3106937090ns5:CurrentFinancialInstruments2022-12-3106937090ns5:ShareCapital2023-12-3106937090ns5:ShareCapital2022-12-3106937090ns5:CapitalRedemptionReserve2023-12-3106937090ns5:CapitalRedemptionReserve2022-12-3106937090ns5:RetainedEarningsAccumulatedLosses2023-12-3106937090ns5:RetainedEarningsAccumulatedLosses2022-12-3106937090ns5:PlantMachinery2023-01-012023-12-3106937090ns5:FurnitureFittings2023-01-012023-12-3106937090ns5:ComputerEquipment2023-01-012023-12-3106937090ns5:PlantMachinery2022-12-3106937090ns5:FurnitureFittings2022-12-3106937090ns5:ComputerEquipment2022-12-3106937090ns5:PlantMachinery2023-12-3106937090ns5:FurnitureFittings2023-12-3106937090ns5:ComputerEquipment2023-12-3106937090ns5:PlantMachinery2022-12-3106937090ns5:FurnitureFittings2022-12-3106937090ns5:ComputerEquipment2022-12-3106937090ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3106937090ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 06937090 (England and Wales)















Competitive Drug Development
International Limited

Unaudited Financial Statements for the Year Ended 31 December 2023






Competitive Drug Development
International Limited (Registered number: 06937090)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Competitive Drug Development
International Limited

Company Information
for the Year Ended 31 December 2023







DIRECTORS: Dr. G Brown
Ms E Hurst





REGISTERED OFFICE: The White House
2 Meadrow
Godalming
Surrey
GU7 3HN





REGISTERED NUMBER: 06937090 (England and Wales)





ACCOUNTANTS: Hughes Waddell
The White House
2 Meadrow
Godalming
Surrey
GU7 3HN

Competitive Drug Development
International Limited (Registered number: 06937090)

Balance Sheet
31 December 2023

31.12.23 31.12.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,714 1,783

CURRENT ASSETS
Debtors 5 47,918 95,112
Cash at bank 138,375 351,136
186,293 446,248
CREDITORS
Amounts falling due within one year 6 38,859 197,902
NET CURRENT ASSETS 147,434 248,346
TOTAL ASSETS LESS CURRENT
LIABILITIES

149,148

250,129

CAPITAL AND RESERVES
Called up share capital 450 450
Capital redemption reserve 225 225
Retained earnings 148,473 249,454
SHAREHOLDERS' FUNDS 149,148 250,129

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Competitive Drug Development
International Limited (Registered number: 06937090)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 September 2024 and were signed on its behalf by:




Dr. G Brown - Director



Ms E Hurst - Director


Competitive Drug Development
International Limited (Registered number: 06937090)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Competitive Drug Development International Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is recognised based on the proportion of work completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Website - 33% on cost
Fixtures and fittings - 25% on reducing balance
Computer equipment - 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Competitive Drug Development
International Limited (Registered number: 06937090)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
Website fittings equipment Totals
£    £    £    £   
COST
At 1 January 2023 3,713 997 15,777 20,487
Additions - 261 1,507 1,768
At 31 December 2023 3,713 1,258 17,284 22,255
DEPRECIATION
At 1 January 2023 3,713 825 14,166 18,704
Charge for year - 142 1,695 1,837
At 31 December 2023 3,713 967 15,861 20,541
NET BOOK VALUE
At 31 December 2023 - 291 1,423 1,714
At 31 December 2022 - 172 1,611 1,783

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Trade debtors 41,608 70,625
Other debtors 6,310 24,487
47,918 95,112

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.23 31.12.22
£    £   
Trade creditors 2,202 28,961
Taxation and social security 4,925 8,625
Other creditors 31,732 160,316
38,859 197,902